Global Peptide CDMO Market Growth (Status and Outlook) 2025-2031

The global Peptide CDMO market size is predicted to grow from US$ 4143 million in 2025 to US$ 9840 million in 2031; it is expected to grow at a CAGR of 15.5% from 2025 to 2031.

Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis.

A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.

CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.

Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. In terms of product categories, it is divided into APIs and intermediates and FDF, with the former holding the major market share of 67%. In terms of application, commercial is the top application area with a market share of 76%, followed by academic research institutions.

LPI (LP Information)' newest research report, the “Peptide CDMO Industry Forecast” looks at past sales and reviews total world Peptide CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide CDMO sales for 2025 through 2031. With Peptide CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide CDMO industry.

This Insight Report provides a comprehensive analysis of the global Peptide CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Peptide CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:
APIs and Intermediates
FDF

Segmentation by Application:
Commercial
Academic Research
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific

Please note: The report will take approximately 2 business days to prepare and deliver.